J07AJ51 • diphtheria + tetanus vaccine + cellular pertussis • Antiinfectives for systemic use | Bacterial vaccines | Pertussis vaccines
The diphtheria, tetanus, whole-cell pertussis (DTPc) vaccine is used to prevent diphtheria, tetanus, and whooping cough (pertussis), three serious infectious diseases caused by bacteria. The vaccine contains diphtheria and tetanus toxoids, as well as inactivated whole cells of Bordetella pertussis, which stimulate the immune system to produce specific antibodies against these pathogens.
The vaccine is administered intramuscularly, usually in multiple doses, according to recommended vaccination schedules for infants and young children. Booster doses are required at regular intervals to maintain immunity.
Common side effects include pain at the injection site, mild fever, fatigue, and irritability. In rare cases, severe allergic reactions may occur.
The DTPc vaccine is an essential measure for protecting public health, helping to reduce the incidence and severity of these infectious diseases and prevent the severe complications associated with them.
Substance: diphtheria + tetanus vaccine + cellular pertussis
Date of last drug list: 01-07-2013
Commercial code: W13382001
Concentration: DT 30 Lf / ml TT 12 UB / ml B.pert
Pharmaceutical form: injection suspension
Quantity: 50
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).